Precision NanoSystems GenVoy-ILM T Cell Kit for mRNA

Tuesday, 01 June, 2021 | Supplied by: ATA Scientific Pty Ltd

The rapid development of COVID-19 vaccines using lipid nanoparticles (LNP) to encapsulate mRNA has demonstrated the power of LNP technology. This novel approach has opened up opportunities for the manufacture of gene-edited cell therapies and in vivo gene targeting.

The GenVoy-ILM T Cell Kit for mRNA is a cell therapy reagent optimised for the delivery of mRNA into activated primary human T cells. Using LNPs designed to exploit endogenous uptake pathways, the method efficiently delivers mRNA into activated human primary T cells to mediate titratable, uniform protein expression levels with high cell viability. The kit enables a high proportion of T cells to be engineered, which should make it a more potent gene delivery method than electroporation.

Preparing mRNA-LNPs from the GenVoy-ILM T Cell Kit for mRNA is quick and simple. Formulated on the NanoAssemblr Spark instrument and cartridges, one preparation takes under 5 min to prepare. The resulting mRNA-LNPs are also compatible with established T cell culture media, allowing rapid integration into existing workflows.

The combination of non-disruptive mRNA delivery technology and seamless integration with cell culture protocols eliminates cell recovery times post-treatment to accelerate the production of T cell therapies.

For more information:

Phone: 02 9541 3500
Related Products

GenScript COVID-19 virus antigens and antibodies

GenScript has developed a comprehensive range of products that scientists may use to accelerate...

ProSci single-domain antibodies

ProSci's sdAb products are designed to introduce a further capability to research regimens in...

GeneTex zebrafish antibodies

The antibodies have been tested on zebrafish samples in a variety of applications including, but...

  • All content Copyright © 2021 Westwick-Farrow Pty Ltd